Predictors of mortality and burden of arrhythmias in endstage heart failure

Endurance Evbayekha1, Akanimo Antia1, Brittany Dixon1

  • 1St. Luke's Hospital, Chesterfield, Missouri.

PubMed

Insights

End-stage heart failure patients frequently have atrial fibrillation. Ventricular fibrillation, atrial fibrillation, supraventricular tachycardia, and ventricular tachycardia independently increase mortality risk in these patients.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Public Health

Background:

  • Heart failure (HF) is a leading cause of death in the U.S.
  • End-stage HF (eHF) significantly impairs quality of life.
  • Understanding eHF comorbidities is crucial for patient outcomes.

Purpose of the Study:

  • To investigate the prevalence of arrhythmias in eHF patients.
  • To assess the independent mortality risk associated with various arrhythmias in eHF.
  • To identify key risk factors impacting survival in eHF.

Main Methods:

  • Utilized ICD-10 code I5084 for eHF identification in the National Inpatient Sample (2016-2020).
  • Employed multivariable logistic regression to analyze mortality probability.
  • Focused on in-hospital mortality risk across different arrhythmia cohorts.

Main Results:

  • Identified 22,703 hospitalizations with eHF (mean age 67).
  • Atrial fibrillation (AFIB) was present in 50.4% of eHF patients.
  • Ventricular fibrillation (VFIB), AFIB, supraventricular tachycardia (SVT), and ventricular tachycardia (VT) showed independent mortality risks (aORs: 5.8, 4.3, 1.9, 1.2 respectively).

Conclusions:

  • Approximately half of hospitalized eHF patients have AFIB.
  • VFIB, AFIB, SVT, and VT are independent predictors of mortality in eHF.
  • VFIB poses the highest mortality risk among the studied arrhythmias.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
918
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
950
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424